Takeda latest to partner with Sosei Heptares in GPCR discovery deal

In its second deal in the past month, Sosei partnered with Takeda to discover, develop and commercialize small molecules and biologics against multiple undisclosed G protein-coupled receptor targets.

Sosei Group Corp. (Tokyo:4565) is eligible to receive up to $26 million in upfront and near-term payments, plus research funding; and more than $1.2 billion in milestones, plus tiered royalties. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will receive exclusive, worldwide rights to develop and commercialize the resulting programs...